In addition, drug-induced AnxA6 upregulation, delivery of recombinant AnxA6 or AnxA6-targeting antibodies might lead to the development of novel treatment options in lipid disorders, liver dysfunction, several cancers and muscular damage (Section 7.4, Section 7.5 and Section 7.6). Here, ANXA6 is linked to Decreased liver function.